Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Washington University School of Medicine
With
CTI BioPharma
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically documented NSCLC, including squamous cell carcinoma, adenocarcinoma (including bronchoalveolar cell), and large cell anaplastic carcinoma (including giant and clear cell carcinomas).
Eligible Disease Stages: Inoperable IIIA and Selected IIIB
Local radiation oncologist must approve patient eligibility prior to entry on study.
Patients must have measurable disease.
Prior Therapy:
* ≥ 2 weeks since formal exploratory thoracotomy.
* No prior chemotherapy or radiation therapy for NSCLC.
ECOG performance status 0-1
Required Initial Laboratory Values (must be submitted within 16 days prior to registration):
* Granulocytes ≥ 1,500/µl
* Platelets ≥ 100,000/µl
* Calculated Creatinine Clearance ≥ 20 cc/min
* Bilirubin \< 1.5 mg/dl
* AST (SGOT) \< 2 x ULN
* INR \> 0.8 \< 1.2\* \*Values apply exclusively to patients not being treated with warfarin. Values for patients being treating with warfarin should fall within the following therapeutic range: \> 2.0 \< 3.0.
You may not be if
Currently active second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse.
Pregnant or nursing because of significant risk to the fetus/infant.
Age \<18 years.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
No HIV-positive patients receiving combination anti-retroviral therapy. Because patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy
One-second forced expiratory volume (FEV1) \<50% or hemoglobin-corrected carbon monoxide diffusion capacity (DLCO) \<50% of predicted, as measured within 21 days of study entry
Symptoms of esophageal dysfunction (dysphagia, odynophagia, or inability to swallow solid food) within 4 weeks prior to study randomization. Patients must not require prophylactic placement of percutaneous enterogastrostomy (PEG) tube or other non-oral nutritional supplement methods
Weight loss of \> 10% in the past 3 months.
Clareo Health | A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer
